A股異動丨立訊精密(002475.SZ)漲5% 計劃收購緯創兩家子公司 或成iPhone新代工廠
格隆匯7月20日丨立訊精密(002475.SZ)漲5%,報57.92元,總市值4045億元。

立訊精密發佈公告稱,立訊精密及其控股股東立訊有限公司將出資33億元人民幣(約合4.72億美元)全資收購緯創資通兩家全資子公司100%的股權。其中,上市公司立訊精密在此次收購中出資6億。
立訊精密目前和歌爾股份同為蘋果Airpods耳機的代工廠。而緯創從2017年開始為蘋果的iPhone手機做代工,是蘋果iPhone的第三大代工廠,但其規模小於富士康和和碩。立訊精密的此次收購,將使得公司有能力承接蘋果iPhone手機的代工,具備重大的戰略意義。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.